GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ACADIA Pharmaceuticals Inc (FRA:DR6) » Definitions » E10

ACADIA Pharmaceuticals (FRA:DR6) E10 : €-1.67 (As of Mar. 2024)


View and export this data going back to 2004. Start your Free Trial

What is ACADIA Pharmaceuticals E10?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.

ACADIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was €0.092. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is €-1.67 for the trailing ten years ended in Mar. 2024.

During the past 3 years, the average E10 Growth Rate was -8.40% per year. During the past 5 years, the average E10 Growth Rate was -10.80% per year. During the past 10 years, the average E10 Growth Rate was -6.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.

During the past 13 years, the highest 3-Year average E10 Growth Rate of ACADIA Pharmaceuticals was 26.00% per year. The lowest was -14.00% per year. And the median was -4.60% per year.

As of today (2024-05-21), ACADIA Pharmaceuticals's current stock price is €13.48. ACADIA Pharmaceuticals's E10 for the quarter that ended in Mar. 2024 was €-1.67. ACADIA Pharmaceuticals's Shiller PE Ratio of today is .


ACADIA Pharmaceuticals E10 Historical Data

The historical data trend for ACADIA Pharmaceuticals's E10 can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ACADIA Pharmaceuticals E10 Chart

ACADIA Pharmaceuticals Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
E10
Get a 7-Day Free Trial Premium Member Only Premium Member Only -1.12 -1.19 -1.47 -1.70 -1.67

ACADIA Pharmaceuticals Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
E10 Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.69 -1.71 -1.86 -1.67 -1.67

Competitive Comparison of ACADIA Pharmaceuticals's E10

For the Biotechnology subindustry, ACADIA Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ACADIA Pharmaceuticals's Shiller PE Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ACADIA Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:

* The bar in red indicates where ACADIA Pharmaceuticals's Shiller PE Ratio falls into.



ACADIA Pharmaceuticals E10 Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.

What is E10? How do we calculate E10?

E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.

We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, ACADIA Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2024 was:

Adj_EPS= Earnings per Share (Diluted) /CPI of Mar. 2024 (Change)*Current CPI (Mar. 2024)
=0.092/131.7762*131.7762
=0.092

Current CPI (Mar. 2024) = 131.7762.

ACADIA Pharmaceuticals Quarterly Data

per share eps CPI Adj_EPS
201406 -0.162 100.560 -0.212
201409 -0.194 100.428 -0.255
201412 -0.227 99.070 -0.302
201503 -0.370 99.621 -0.489
201506 -0.347 100.684 -0.454
201509 -0.347 100.392 -0.455
201512 -0.413 99.792 -0.545
201603 -0.404 100.470 -0.530
201606 -0.561 101.688 -0.727
201609 -0.544 101.861 -0.704
201612 -0.616 101.863 -0.797
201703 -0.673 102.862 -0.862
201706 -0.490 103.349 -0.625
201709 -0.445 104.136 -0.563
201712 -0.465 104.011 -0.589
201803 -0.357 105.290 -0.447
201806 -0.437 106.317 -0.542
201809 -0.429 106.507 -0.531
201812 -0.439 105.998 -0.546
201903 -0.522 107.251 -0.641
201906 -0.336 108.070 -0.410
201909 -0.263 108.329 -0.320
201912 -0.306 108.420 -0.372
202003 -0.516 108.902 -0.624
202006 -0.240 108.767 -0.291
202009 -0.458 109.815 -0.550
202012 -0.345 109.897 -0.414
202103 -0.353 111.754 -0.416
202106 -0.224 114.631 -0.258
202109 -0.077 115.734 -0.088
202112 -0.239 117.630 -0.268
202203 -0.636 121.301 -0.691
202206 -0.199 125.017 -0.210
202209 -0.172 125.227 -0.181
202212 -0.245 125.222 -0.258
202303 -0.252 127.348 -0.261
202306 0.009 128.729 0.009
202309 -0.375 129.860 -0.381
202312 0.257 129.419 0.262
202403 0.092 131.776 0.092

Add all the adjusted EPS together and divide 10 will get our e10.


ACADIA Pharmaceuticals  (FRA:DR6) E10 Explanation

If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.

For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.

The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.


Be Aware

Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.


ACADIA Pharmaceuticals E10 Related Terms

Thank you for viewing the detailed overview of ACADIA Pharmaceuticals's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.


ACADIA Pharmaceuticals (FRA:DR6) Business Description

Traded in Other Exchanges
Address
12830 El Camino Real, Suite 400, San Diego, CA, USA, 92130
Acadia Pharmaceuticals Inc is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.

ACADIA Pharmaceuticals (FRA:DR6) Headlines

No Headlines